Twice- vs. thrice-weekly moderate hypofractionated radiotherapy for prostate cancer: does overall treatment time matter?

Achard, Verane; Jorcano, Sandra; Rouzaud, Michel; Escudé, Lluís; Miralbell, Raymond; Zilli, Thomas

doi:10.1007/s00432-019-02893-4

Scientific article

English

Twice- vs. thrice-weekly moderate hypofractionated radiotherapy for prostate cancer: does overall treatment time matter?

ContributorsAchard, Verane; Jorcano, Sandra; Rouzaud, Michel; Escudé, Lluís; Miralbell, Raymond; Zilli, Thomas

Published inJournal of Cancer Research and Clinical Oncology, vol. 145, no. 6, p. 1581-1588

Publication date2019

Abstract

To evaluate the influence of overall treatment time (OTT) in disease control, acute, and long-term side effects with moderate hypofractionated external beam radiotherapy (RT) for prostate cancer (PCa) delivered either twice- or thrice-a-week.

Keywords

Hypofractionation
Overall treatment time
Prostate cancer
Radiotherapy
Toxicity

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de radiologie et informatique médicale

Research groups

Laboratoire de radiothérapie de haute précision pour le cancer de la prostate (1014)

Citation (ISO format)

ACHARD, Verane et al. Twice- vs. thrice-weekly moderate hypofractionated radiotherapy for prostate cancer: does overall treatment time matter? In: Journal of Cancer Research and Clinical Oncology, 2019, vol. 145, n° 6, p. 1581–1588. doi: 10.1007/s00432-019-02893-4

Article (Published version)

Identifiers

PID : unige:135381
DOI : 10.1007/s00432-019-02893-4
PMID : 30887155

Additional URL for this publicationhttp://link.springer.com/10.1007/s00432-019-02893-4

Journal ISSN0171-5216

230views

0downloads

Creation28/04/2020 17:28:00

First validation28/04/2020 17:28:00

Update time15/03/2023 21:51:37

Status update15/03/2023 21:51:36

Last indexation31/10/2024 18:32:35

Archive ouverte UNIGE

Twice- vs. thrice-weekly moderate hypofractionated radiotherapy for prostate cancer: does overall treatment time matter?

To evaluate the influence of overall treatment time (OTT) in disease control, acute, and long-term side effects with moderate hypofractionated external beam radiotherapy (RT) for prostate cancer (PCa) delivered either twice- or thrice-a-week.

Technical informations